Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates strong financial growth with a 1321% revenue increase in 2024 and a projected revenue surpassing in Q1 2025. The acquisition of Livecom is expected to cut operational costs significantly, and the company has a solid cash position. Despite market challenges and risks, the strategic shift to social commerce and a diversified revenue stream is promising. Shareholder equity has improved dramatically. The positive guidance and operational improvements suggest a positive stock price movement in the near term.
Total Revenue for Q4 2024 $723,000, an increase of $694,000 over the same period last year, representing revenue growth of almost 2400%.
Total Revenue for FY 2024 $895,000, an increase of $832,000 over 2023, representing revenue growth of 1321%.
Revenue for Q3 2024 $490,000, an increase of $595,000 compared to Q3 2024, representing growth of almost 465% quarter over quarter.
Cash Runway Cash runway conservatively assuming zero revenue growth well into 2028 and beyond.
Shareholder Equity Increased from almost $2,000,000 negative in June 2023 to more than $16,000,000 positive in December 2024.
Operational Cost Reduction from Livecom Acquisition Anticipated direct operational cost reduction of approximately $1,000,000 per year.
Net Cash Value per Common Share At least $13.5 per share, based on under 1,000,000 shares issued and outstanding as of 12/31/2024.
New Product Launches: Launched 'Vanity Prescribed' in the telehealth industry and 'Good Girl RX' in partnership with Savannah Chrisley. Developed 'GoFund Yourself', a crowdfunding marketing platform, generating $233,000 in Q4.
Market Expansion: Shifted focus to the telehealth industry and social commerce, with significant revenue growth in the new market.
Operational Efficiencies: Acquired Livecom's technology, resulting in an anticipated operational cost reduction of approximately $1,000,000 per year.
Strategic Shifts: Transitioned from a direct sales SaaS model to a diversified business model focusing on telehealth and social commerce.
Market Conditions: The company faced challenging market conditions that impeded value creation, particularly in the direct sales SaaS business, leading to a strategic shift away from that model.
High Attrition Rates: The high attrition rate among sales reps in the direct sales companies made it difficult and costly to generate meaningful revenue growth.
Regulatory and Economic Changes: The company recognized the need to diversify revenue streams to insulate itself from economic and regulatory changes affecting its customer base.
Predatory Financing Terms: The company experienced predatory financing terms that eroded share prices and led to reverse splits and delistings, impacting overall financial health.
Capital Market Pressures: The capital markets environment created challenges for small and micro-cap companies, leading to increased vulnerability to short selling and negative market sentiment.
Supply Chain Challenges: The company faced challenges in developing and maintaining a reliable supply chain for its new telehealth business, impacting revenue growth.
Competition: The competitive landscape included aggressive pricing strategies from competitors, which necessitated continued R&D expenditures and impacted profitability.
AI Integration Risks: The integration of AI technology from Livecom posed risks related to operational costs and the potential for future acquisition by competitors.
Debt Management: Successfully paid off all debt and redeemed previously issued preferred shares, resulting in a debt-free balance sheet.
Revenue Diversification: Launched new business units including Vanity Prescribed, Good Girl RX, and GoFund Yourself to diversify revenue streams.
AI Integration: Acquired Livecom to enhance AI capabilities, expecting a direct operational cost reduction of approximately $1,000,000 per year.
Market Strategy: Shifted focus to social commerce, resulting in exponential revenue growth.
Revenue Expectations: Expect Q1 2025 revenue to surpass Q4 2024 revenue.
Financial Projections: Combined 2024 revenue was $895,000, a 1321% increase over 2023.
Cash Position: Projected cash runway well into 2028 assuming zero revenue growth.
Net Cash Value: Net cash value per common share is at least $13.5.
Shareholder Equity: Shareholder equity increased from almost $2,000,000 negative in June 2023 to more than $16,000,000 positive in December 2024.
Share Float: The company executed a reverse split resulting in less than 1,000,000 shares float.
Net Cash Value per Common Share: The net cash value per common share is at least $13.5.
Cash and Securities: The company has more than $1,000,000 in cash and highly liquid securities.
The earnings call highlights significant revenue growth, a strategic acquisition, and a strong financial position with zero debt. Despite risks related to the business model change and acquisition, the improved EPS and optimistic future outlook support a positive sentiment. The Q&A indicates management's confidence in further growth and successful integration of new technology. However, the absence of a share buyback program and some uncertainties in management responses temper the overall sentiment, resulting in a moderate positive outlook for the stock.
The earnings call reveals significant revenue growth, strategic acquisitions, and a strong cash position with zero debt. The company has secured high-profile clients, enhancing its market position. The non-dilutive funding deal and 9% dividend are shareholder-friendly. Despite some risks, such as competitive pressures, the overall sentiment is very positive due to strong growth metrics and optimistic future expectations. The lack of specific revenue guidance is a minor concern but doesn't outweigh the positive aspects. Small-cap stocks like Verb are likely to react strongly, justifying a 'Strong positive' prediction.
The earnings call indicates strong financial growth with a 1321% revenue increase in 2024 and a projected revenue surpassing in Q1 2025. The acquisition of Livecom is expected to cut operational costs significantly, and the company has a solid cash position. Despite market challenges and risks, the strategic shift to social commerce and a diversified revenue stream is promising. Shareholder equity has improved dramatically. The positive guidance and operational improvements suggest a positive stock price movement in the near term.
The earnings call reveals significant revenue growth, a strong cash position, and a debt-free status, which are positive indicators. The company's strategic initiatives, such as entering the telehealth market and acquiring LyveCom, suggest potential for future growth. Despite facing market challenges, the optimistic guidance for Q1 2025 and diversified revenue streams contribute to a positive outlook. Shareholder equity improvements and a high net cash value per share further support a positive sentiment. Overall, these factors suggest a likely stock price increase in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.